EQT Nexus

EQT Nexus is an evergreen investment strategy and semi-liquid fund managed by EQT, a leading global investment organization. Launched in 2023, the fund provides individual and institutional investors with access to EQT's diversified private market portfolio, focusing on flagship Private Equity and Infrastructure strategies. In the healthcare and life sciences sectors, EQT Nexus co-invests alongside EQT Life Sciences in innovative biotechnology companies and commercial-stage healthcare ventures. Key recent investments include supporting Tenpoint Therapeutics' launch of Yuvezzi for presbyopia and funding Sensorion's gene therapy programs for genetic hearing loss. The fund operates with a flexible structure that allows for monthly subscriptions and quarterly redemptions, bridging the gap between private wealth and institutional-grade private equity assets.